What is the $35 insulin cap and who qualifies?

The Inflation Reduction Act of 2022 created a $35/month cap on insulin for Medicare Part D enrollees, effective January 2023. This cap applies to all covered insulin products in your Part D plan's formulary and is not income-based — all Medicare Part D enrollees qualify. Separately, most ACA marketplace plans are required to cover at least one insulin product per category (rapid-acting, intermediate, long-acting) at $35/month or less per benefit period.

Can I buy insulin over the counter without a prescription?

Some insulin formulations are available over the counter at Walmart pharmacies. Walmart's ReliOn brand Regular human insulin (R) and NPH human insulin (N) cost approximately $25/vial without a prescription or insurance. Important caveat: these are older human insulin formulations, not the modern analog insulins (like Humalog, NovoLog, or Lantus) that most people with Type 1 or well-controlled Type 2 diabetes use. Switching insulin types should only be done with physician guidance due to differences in onset and duration.

What are biosimilar insulins and are they cheaper?

Biosimilar insulins are biologically similar versions of brand-name insulin analogs, approved by the FDA. Examples include Rezvoglar (biosimilar to Lantus/glargine) and Semglee (also glargine biosimilar). They are therapeutically equivalent to the brand-name products. List prices for biosimilars are typically 40–65% lower than brand-name insulins, and GoodRx prices are often $30–$60 per vial. Your formulary tier for biosimilars may be more favorable than for brand-name products — check your plan's drug formulary.

What do I do if my insurer denies coverage for my insulin?

First, check if your plan covers a biosimilar or alternative insulin in the same category (rapid-acting, intermediate, or long-acting) and whether your doctor can prescribe that instead. If your specific insulin was denied and no equivalent is covered, file an internal appeal — your doctor must submit a letter of medical necessity explaining why that specific formulation is required. If the appeal is denied, request external review. Insulin denials are often reversed on appeal when supported by physician documentation.

How Much Does Insulin Cost in 2026? (With & Without Insurance)

Q: How much does insulin cost per month in 2026?

It varies enormously by insurance status and which programs you use. Medicare Part D beneficiaries pay a $35/month cap per covered insulin product under the Inflation Reduction Act. ACA marketplace enrollees pay $35/month or less for covered insulins. Uninsured patients can pay $100–$300+ per vial at retail without discounts — but Walmart ReliOn insulin costs $25/vial over the counter (Regular and NPH formulations only), and manufacturer assistance programs can reduce costs to $0–$99/month for brand-name insulins.

The list price of insulin in the US bears almost no resemblance to what most patients actually pay — but the gap between those prices can cost uninsured patients hundreds of dollars per month if they don't know their options. The Inflation Reduction Act capped insulin at $35/month for Medicare Part D enrollees. Manufacturer savings programs reduce brand-name insulin to $35–$99/month for many uninsured patients. And BillKarma's analysis found that insulin billing errors affect 12% of diabetic patient claims — meaning the price problem isn't just what you pay at the pharmacy.

1. 2026 insulin prices: list, insured, and uninsured

There are three very different prices for insulin: the list price (what no one actually pays), the insured price (what patients with coverage pay after copays/deductibles), and the real uninsured price (what patients without insurance and without discount programs pay).

Insulin brand	Type	List price/vial	GoodRx approx.	Medicare Part D (cap)	Manufacturer program
Humalog (lispro)	Rapid-acting analog	$274–$325	$70–$110	$35/mo cap	Lilly Insulin Value Program: $35/mo
NovoLog (aspart)	Rapid-acting analog	$289–$340	$75–$120	$35/mo cap	Novo Nordisk Patient Assistance
Lantus (glargine)	Long-acting analog	$292–$360	$80–$130	$35/mo cap	Sanofi Insulins Valyou: up to $99/mo
Basaglar (glargine)	Long-acting analog (follow-on)	$168–$215	$55–$95	$35/mo cap	Lilly Insulin Value Program: $35/mo
Rezvoglar (glargine biosimilar)	Long-acting biosimilar	$92–$130	$30–$60	$35/mo cap	Lilly program eligibility varies
Semglee (glargine biosimilar)	Long-acting biosimilar	$90–$125	$28–$55	$35/mo cap	Biocon patient assistance
Walmart ReliOn Regular (R)	Short-acting human insulin	$25/vial OTC	N/A — OTC	N/A — OTC	N/A
Walmart ReliOn NPH (N)	Intermediate human insulin	$25/vial OTC	N/A — OTC	N/A — OTC	N/A

Prices are approximate and vary by pharmacy, state, and plan. GoodRx prices reflect coupon pricing available as of early 2026. Always verify current pricing at your pharmacy.

2. The $35 Medicare cap (Inflation Reduction Act)

The Inflation Reduction Act of 2022 created a $35/month per covered insulin cap for Medicare Part D beneficiaries, effective January 1, 2023. Key details:

Who qualifies: All Medicare Part D enrollees — no income test, no application required
Which insulins: All covered insulin products in your Part D plan's formulary. If your insulin is on the formulary, your copay is capped at $35/month per product.
Deductible phase: The $35 cap applies even during the deductible phase — you never pay the full list price even before your deductible is met
Per product: If you use two insulins (e.g., rapid-acting and long-acting), each is capped at $35/month separately
Medicare Advantage: Part C (Medicare Advantage) plans that include Part D drug coverage are also required to apply the $35 cap

If you are being charged more than $35/month for a covered insulin under Medicare Part D, contact your plan and ask them to apply the Inflation Reduction Act cap. If they refuse, file a complaint with CMS at 1-800-MEDICARE.

3. ACA marketplace insulin coverage

Under rules that took effect for plan years beginning in 2023, most ACA marketplace plans must cover at least one insulin product in each of the following categories at no more than $35/month per covered insulin:

Rapid-acting insulin (e.g., Humalog, NovoLog, or biosimilar equivalent)
Short-acting insulin (Regular human insulin)
Intermediate-acting insulin (NPH)
Long-acting insulin (e.g., Lantus, Basaglar, or biosimilar)
Pre-mixed insulin combinations

Key caveats:

The cap applies to covered insulins on your plan's formulary — your plan may cover a biosimilar but not a specific brand-name product at the $35 cap rate
The $35 applies per benefit period (typically per 30-day supply), not per vial — if you use more than one vial per month, the cap still applies to the total monthly supply
Some grandfathered or transitional plans may not be subject to this requirement — check with your plan

Read your formulary before your prescription is filled. The specific insulin covered at the $35 cap rate may differ from what you've been prescribed. Ask your pharmacist which covered insulins qualify — then ask your doctor if switching is clinically appropriate.

4. Manufacturer savings programs

All three major insulin manufacturers operate patient assistance programs. These programs provide insulin free or at a steep discount to qualifying patients:

Eli Lilly: Lilly Insulin Value Program

Cost: $35/month per prescription, regardless of quantity needed (up to a cap)
Eligibility: US residents, including insured patients who are paying out of pocket or have insurance that doesn't cover insulin
Products covered: Humalog, Basaglar, Rezvoglar, and other Lilly insulins
How to apply: insulinaffordability.com or at participating pharmacies
Income limit: None for the $35 program; additional free drug programs available for lower-income patients

Novo Nordisk: Patient Assistance Program

Products covered: NovoLog, Levemir, Tresiba, Victoza, and others
Eligibility: Uninsured or underinsured US residents who meet income criteria (typically under 400% FPL)
How to apply: novonordisk-us.com/patients/patient-assistance.html
For insured patients: NovoCare savings cards available that cap copays

Sanofi: Insulins Valyou Savings Program

Products covered: Lantus, Toujeo, Admelog, Apidra
Cost: As low as $99/month for qualifying patients, with free drug available for very low-income patients
How to apply: insulinsvalyou.com
Income limit: Generally under 400% FPL for the savings program; free drug for patients below 250% FPL

5. Walmart ReliOn and over-the-counter options

Walmart pharmacies sell two insulin products over the counter — no prescription required — for approximately $25 per vial:

ReliOn Regular (R): Short-acting human insulin; used for mealtime dosing; slower onset and longer duration than modern rapid-acting analogs
ReliOn NPH (N): Intermediate-acting human insulin; used for background insulin coverage; different dosing profile than long-acting analogs like Lantus

Important warnings about OTC human insulin:

Human insulin (R and NPH) has a different onset, peak, and duration than modern analog insulins (like Humalog and Lantus) — dosing protocols are different
People with Type 1 diabetes should only switch insulin types under physician supervision
Syringes for use with vials must be U-100 syringes — available at pharmacies without a prescription in most states
For many Type 2 patients on a simple regimen, ReliOn may be clinically appropriate — but confirm with your provider first

6. Biosimilar insulins: cheaper alternatives

Biosimilar insulins have been approved by the FDA and are therapeutically interchangeable with the brand-name products they are based on. They typically cost 40–65% less at list price, and even more with discounts:

Biosimilar	Reference product	FDA status	Approx. GoodRx price
Rezvoglar (insulin glargine-aglr)	Lantus (glargine)	Interchangeable biosimilar	$30–$60/vial
Semglee (insulin glargine-yfgn)	Lantus (glargine)	Interchangeable biosimilar	$28–$55/vial
Insulin lispro (authorized generic)	Humalog	Authorized generic	$35–$65/vial
Insulin aspart (authorized generic)	NovoLog	Authorized generic	$40–$70/vial

If your formulary places brand-name insulin in a higher tier (higher copay) than a biosimilar equivalent, ask your doctor to prescribe the biosimilar. They are interchangeable — your pharmacist can substitute the biosimilar for the brand name in most states without a new prescription.

7. State insulin cost caps

Several states have enacted insulin cost caps for state-regulated insurance plans:

California: $35/month cap on insulin cost-sharing for state-regulated health plans
Colorado: $35/month cap on insulin for state-regulated plans; also limits testing supply copays
New York: $100/month cap on insulin for state-regulated plans
Maine, New Hampshire, Illinois, Virginia, and others: Various caps and cost-sharing limits — check your state insurance commissioner's website

Note: These state laws apply to state-regulated insurance plans — primarily individual and small group plans sold in the state. They do not apply to self-insured employer plans (which are regulated by federal ERISA law, not state law), which cover roughly 60% of insured workers.

8. How to fight an insurance denial for insulin

Insulin denials often cite "not medically necessary," "not on formulary," or "step therapy required." Here is how to fight back:

Check your formulary first. Log into your insurance portal and look up your specific insulin. If a biosimilar or alternative is covered at a lower tier, ask your doctor if switching is clinically appropriate — this is the fastest path.
File an exception request. If your specific insulin isn't covered or is placed at a high cost-sharing tier, your doctor can file a formulary exception request stating why the covered alternative is not clinically appropriate for you. For insulin, this often succeeds when documented by an endocrinologist.
Challenge step therapy. If your insurer requires you to try a different insulin first (step therapy), your doctor can request a step therapy override by documenting: (a) you have already tried the required alternative, (b) it was ineffective or caused adverse effects, or (c) starting with the alternative would be clinically contraindicated.
Internal appeal. If the exception or override is denied, file a formal internal appeal. You have 180 days from a denial. Your appeal should include a letter of medical necessity from your endocrinologist and any relevant clinical documentation.
External review. After exhausting internal appeals, request independent external review. For insulin denials tied to life-sustaining medication, most states and plans allow expedited external review within 72 hours.

BillKarma's data shows that insulin billing errors affect 12% of diabetic patient claims — including incorrect quantity billing, wrong product codes, and duplicate charges. If you've received a bill for insulin-related care, upload it to BillKarma to check for errors before paying.

Frequently asked questions

How much does insulin cost per month in 2026?

Medicare Part D enrollees: $35/month cap. ACA marketplace plans: $35/month for covered insulins. Uninsured with manufacturer programs: $35–$99/month. Uninsured without any programs: $100–$300+ per vial at list price. Walmart ReliOn human insulin (older formulation): $25/vial OTC. Biosimilars with GoodRx: $28–$70/vial.

Does the $35 insulin cap apply to me if I'm not on Medicare?

If you have an ACA marketplace plan, most plans must cover at least one insulin per category at $35/month. If you have an employer-sponsored plan, the $35 cap is not federally required — but many employers have voluntarily adopted it. Check your plan's Summary of Benefits or call member services. For employer plans that haven't adopted a cap, manufacturer savings programs are the next option.

Can I switch from Lantus to a biosimilar to save money?

Rezvoglar and Semglee are FDA-approved interchangeable biosimilars to Lantus — meaning your pharmacist can substitute either for Lantus without a new prescription in most states. They have the same active ingredient (insulin glargine) and are clinically equivalent. The list price is 40–65% lower. If your plan covers a biosimilar at a lower cost-sharing tier, this is a straightforward way to reduce your monthly cost.

What is the Lilly Insulin Value Program?

Eli Lilly's program caps out-of-pocket costs for its insulins (Humalog, Basaglar, Rezvoglar, and others) at $35/month per prescription for US residents — regardless of insurance status. There is no income limit for the $35 program. Apply at insulinaffordability.com or ask your pharmacist to run the Lilly savings card.

Can insulin billing errors cause me to be overcharged?

Yes. BillKarma's analysis found that 12% of diabetic patient claims contain billing errors — including incorrect quantity units (billing for more vials than dispensed), incorrect product codes, duplicate charges, and billing for supplies not provided. If you've received a medical bill involving insulin or diabetes management, review the itemized charges carefully. Upload your bill to BillKarma to check for errors before paying.